ClinPhone already has a number of large pharmaceutical clients based in France that have benefited from using ClinPhone’s clinical technologies. This new office will provide both its current and new customers within this region with a local point of contact.

Damien Tremolet, Director of Operations at ClinPhone, will lead the new office, which is centrally located in the business center of the Gare de Lyon station in Paris, France. He will be supported by Jacques Rudelle, an Associate Director of Business Development at ClinPhone.

A clear objective for ClinPhone has been to seek market opportunities and growth areas in Europe to specifically establish a first line physical presence. Having a local presence enables ClinPhone to provide increased face-to-face contact, trial consultations and expert advice in local languages.

“Customer service is a vital part of any successful business and ClinPhone prides itself on providing the best possible support to all of its clients regardless of location,” comments Steve Kent, CEO, ClinPhone. “The opening of this new office is testament to our continued unwavering commitment and we are very excited about our expansion.”

ClinPhone has a comprehensive portfolio of clinical technology solutions, including its newly-launched DataLabs by ClinPhone (EDC) and ClinPhone Randomization and Trial Supply Management (IVR/IWR) integrated solution, electronic data capture (EDC), randomization, trial supply management, drug accountability, electronic patient reported outcomes (ePRO), clinical trial management systems (CTMS) and integration solutions. ClinPhone is the first company of its kind to offer such a comprehensive suite of software and services to the biopharmaceutical industry.

ClinPhone provides a range of clinical technology solutions to many of the world’s leading pharmaceutical and biotechnology companies. The company is the largest and most accomplished Clinical Technology Organization (CTO) in the industry, with experience in over 2,000 trials.

For further information on ClinPhone’s clinical trial technology solutions, please visit www.clinphone.com, or alternatively e-mail info@clinphone.com.

About ClinPhone
ClinPhone plc is the world’s largest Clinical Technology Organization (CTO) with an unrivaled track record of innovation in the development of clinical trial technology. Headquartered in Nottingham UK with offices around the world, ClinPhone works with leading global biotechnology organizations, pharmaceutical companies and Contract Research Organizations (CROs).

ClinPhone is the largest and most accomplished CTO with experience in over 2,000 clinical trials spanning 88 countries and 71 languages. The Company’s experience includes Phase I to Phase IV studies, ranging from single center studies with 20 patients to “mega trials” with over 40,000 patients.

ClinPhone’s product portfolio, consisting of software and services, is backed by continuous research and investment in the latest technologies, coupled with extensive in-depth clinical industry experience. Its industry-leading software solutions include electronic data capture (EDC) and clinical trial management systems (CTMS), which can be licensed or implemented as hosted solutions. Delivered via its renowned Interactive Voice Response (IVR) and Interactive Web Response (IWR) platform, ClinPhone offers randomization, trial supply management, trial supply simulation, electronic patient reported outcomes (ePRO), and patient recruitment solutions.

ClinPhone’s products can integrate, taking the pain out of juggling and managing multiple sources of disparate information. This approach provides more control over data, improves data integrity and streamlines the data validation process.

For further press information contact: Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom Tel: + 44 1477 539539. Fax: +44 1477 539540 E:clinphone@scottpr.com

The agreement was signed by Dr. Villoo Morawala-Patell, Founder, Chairperson and Managing Director, AVESTHAGEN LIMITED and Dr. Abdulqader Alkhayat, Executive Director of DuBiotech. The first project to be undertaken will include the launch and commercialization of BioPerceptä, an eco-friendly and biodegradable plastic in the Gulf Cooperation Council (GCC) region and also establish a conversion plant to process BioPerceptä within the next two years. This alternate biodegradable plastic breaks down and becomes compost in a matter of 120 days under industrial composting conditions. The joint venture will explore future opportunities in the areas of Environment Adjusted Cropsä, AgriBiotech, bioActives for the food and beverage industry, Genome Project, Herb-Based projects among others.

Commenting on this landmark occasion, Dr Villoo Morawala-Patell, Founder, Chairperson & Managing Director, AVESTHAGEN LIMITED said, “We are extremely glad to partner with DuBiotech to explore joint possibilities of further science and research in the life sciences segment. The launch of BioPerceptä, a biodegradable plastic, is our way of contributing back to the environment we live in. As research and innovation is core to AVESTHAGEN, we would not stop here, but continue our work to introduce more environment friendly products.”

Announcing the development, Mr. Simon Daniel, Chief Executive – Marketing, IBPL, said, “To give impetus to IBPL’s sales activities, the company plans to launch one more new division BRIDGE catering to Nephrology / Neurology therapeutic areas in the calendar year. As part of new sales strategy, IBPL has doubled its sales force to allow more focussed approach towards niche therapeutic areas of Oncology. Additionally, new division AQUA will look after sales activity of plasma products namely – Albumin & Globucel – marketed through Celestial Biologicals, associate company of IBPL.”

Intas entered the Indian anti-cancer market in the year 1998 with the launch of Novatech division (oncology marketing division). Starting with a product basket of a few oncology products in 1999, today, IBPL can boast of one of the most comprehensive oncology product basket comprising of 26 products in different dosage forms (capsules, injections, tablets and pre-filled syringes).1

Speaking about oncology product basket and domestic sales operations, Mr. Daniel, said, “IBPL is the only biotech company to manufacture Pegylated GCSF in India and simultaneously market the product under the brand name – Neupeg. The product offers treatment against toxicity caused due to chemotherapy in cancer patients. This USP has prompted the need for a special and dedicated sales division RELAY. As per market estimates, there lies immense untapped potential in Indian Oncology segment. Keeping in view the future product pipeline, increasing the sales force is an important step towards strengthening IBPL’s presence in the domestic market. The onset of new financial year signifies robust sales targets, change in strategy and expansion of team that will collectively add revenues for IBPL.”

PharmaTech 2008, was organised by the Automation Industry Association, to demonstrate to the Indian Pharmaceutical industry about the benefits of leveraging cutting edge automation technologies and responding to the emerging business environment.The symposium brought together leading Automation process & solution providers on a common platform,discussing industry specific challenges of operational excellence, global regulatory and certification requirement, integrated performance management, manufacturing and automation risks and return on assets.

The Indian Pharmaceutical market which today stands at fourth largest in terms of volume and thirteenth in terms of value has achieved over 7% growth, making its presence felt in the global market primarily through its focus on global generics markets. With many governments encouraging the shift to generics on the back of rising pressure on healthcare budgets, coupled with a significant number of drugs going off patent, Indian pharma companies are now pursuing aggressive strategies to foray new and under-served markets such as Japan, South Africa, EU and CIS countries and Latin America. The Indian Biotech industry too has crossed US$ 2 billion and is projected to be US$ 5 billion by year 2010. While automation started and progressed slowly in Pharmaceutical Industry, it has come to play an increasingly important role in keeping the industry moving ahead.

"Pharma companies are likely to take different steps forward as they reshape their strategies and infrastructure to prepare for future developments, but the starting point has to be the vision of where the company wants to be in 10 to 15 years time and how this will impact manufacturing methods and practices' said Mr Venkat Jasti, Chairman Pharmexcil & VC CEO Suven Life Sciences Limited.

"Companies which earlier were competing with each other with stand-alone equipment, lower production costs, and a market scenario where markets were defined by products are now looking at a new era in manufacturing. Competition is today in terms of value chains, with a lot more emphasis on time and delivery cost to market. Manufacturing firms have to look at a scenario where they have to sense the customers need and respond immediately. Integrated automation in this situation has become a must rather than a mere requirement" added Mr Singh.

Operational effectiveness, profit pressures require manufacturing to contribute and the industry has to work together to enable a compliant manufacturing environment that delivers product to plan with minimal cost and risk. The role of automation technologies is thus crucial in facilitating processes that enable measurement and control, ensure optimum efficiency and increase productivity. Automation is also the key in maintaining consistency & quality and conforming to safety, environmental and a host of other stringent regulatory standards.

"Automation is required to unlock full value of the Business Chain by connecting plant floor to business system , and connectivity to the business system from R&D, through Clinical trial to Commercial Manufacturing" continued Mr Jasti.